Here’s how a loophole in a transparency law can distort medical practices
A loophole in a transparency law lets biotechs pay doctors to review, test, or even promote their experimental drugs — without publicly reporting it.
For the past four years, the federal government has required drug makers to report any meals they buy for doctors, as well as any payments for speaking, consulting, and running clinical trials.
The system has succeeded in shining a light on financial ties that may unduly influence medical practice and research, a concern heightened by a series of pharma scandals involving illegal marketing, as well as studies showing such payments sway prescribing.
There is,
